Keynote091和Keynote671本来的设计上是很理想的辅助赢一次,围术期新辅助赢一次。辅助K药获批算是先赢了一局。 不过没关系,这次想赢就得来点曲折的操作,预判你的预判。671初步结果虽然很尴尬让大家继续期待后续结果(这篇NEJM数据data-cutoff date, Jul...
KEYNOTE-671研究两组中取得/未取得pCR的患者的EFS曲线(图2)显示,无论是否取得pCR,帕博利珠单抗组都有更好的生存,而且获益程度明显大于仅有新辅助治疗的CheckMate 816研究类似分析的结果。正如文章作者在讨论部分提到的,KEYNOTE-671研究中...
KEYNOTE-671研究的成功,有望打开帕博利珠单抗新辅助治疗的大门,将其进一步推进贯穿于NSCLC全程治疗。 KEYNOTE-671研究是一项随机、双盲是Ⅲ期试验,旨在评估在可切除II、IIIA、IIIB(T3-4N2)期NSCLC患者中,帕博利珠单抗联合化疗作为新辅助疗法,并在患者术后使用帕博利珠单抗单药辅助治疗的疗效与安全性。该试验的双重主...
Key studies in earlier stages of NSCLC include KEYNOTE-671, KEYNOTE-091, KEYNOTE-867, KEYLYNK-012 and KEYVIBE-006. About KEYNOTE-671 KEYNOTE-671 is a randomized, double-blind Phase 3 trial (ClinicalTrials.gov, NCT03425643...
In KEYNOTE-671, adverse reactions occurring in patients with resectable NSCLC receiving KEYTRUDA in combination with platinum-containing chemotherapy, given as neoadjuvant treatment and continued as single-agent adjuvant treatment, were generally similar to those occurring in patients in other clinical tria...
Health care professionals may find clinical trial results for KEYNOTE-006 (a study in patients with advanced melanoma).
In KEYNOTE-671, adverse reactions occurring in patients with resectable NSCLC receiving KEYTRUDA in combination with platinum-containing chemotherapy, given as neoadjuvant treatment and continued as single-agent adjuvant treatment, were generally similar to those occurring in patients in other clini...
2021年4月,Journal of Clinical Oncology(JCO)报道了KEYNOTE-024研究的第一个5年随访结果。研究中的154名患者接受了帕博利珠单抗治疗,151例患者接受了化疗。在中位随访了55.9个月之后,99名最初接受化疗的患者后续改用抗PD-1单抗或抗PD-L1单抗治疗,有效交叉率为66.0%。
Together with the significant efficacy improvements and absence of new safety signals, HRQoL data support the perioperative pembro regimen as a new standard of care.Clinical trial information: NCT03425643.LSM (95% CI) Change from BL to Neoadj wk 11, Pembro ArmLSM (95% CI) Change from BL ...
9.KEYNOTE-671研究:III期,K药+化疗→手术→K药维持 vs 化疗→手术,EFS获益;确立治疗新模式 术后辅助治疗 10.PEARLS/KEYNOTE-091研究:III期,帕博利珠单抗 vs 安慰剂,DFS为53.6 vs 42.0 个月,PDL1高表达无统计差异 III期不可切除 11.KEYNOTE-799:K药+同步放化疗,ORR约70%。